

Delta values of the ^{13}C -urea breath test in *Helicobacter pylori* positive persons with and without dyspepsia

Stanislav Rejchrt¹, Marcela Kopáčová¹, Ilona Koupil², Viktor Voříšek³, Martin Beránek³, Bohumil Seifert⁴, Oldřich Pozler⁵, Pavel Živný³, Tomáš Douda¹, Martina Kolesárová¹, Michal Pintér¹, Vladimír Palička³, Jan Bureš¹, and the European Society for Primary Care Gastroenterology⁶

Dedicated to Professor Bohumil Fixa, MD, DSc, on the Occasion of his 75th Birthday

¹ Clinical Centre, 2nd Department of Medicine, Charles University Teaching Hospital, Hradec Králové, Czech Republic

² Centre for Health Equity Studies (CHES), Stockholm University, Karolinska Institutet, Stockholm, Sweden

³ Institute of Clinical Biochemistry and Diagnostics, Charles University Teaching Hospital, Hradec Králové, Czech Republic

⁴ Institute of General Practice, First Faculty of Medicine, Charles University, Praha, Czech Republic

⁵ Department of Pediatrics, Charles University Teaching Hospital, Hradec Králové, Czech Republic

⁶ the European Society for Primary Care Gastroenterology, participants in the Project: Eva Jančová, MD (Praha 4), Václav Hanka, MD (Nové Město nad Metují), Miloš Ponižil, MD (Hrušovany nad Jevišovkou), Karel Janík, MD (Horní Bečva), Tomáš Koudelka, MD (Počátky), Irena Holdšvendová, MD (Aš), Jiří Appelt, MD (Chýně), Romana Balatková, MD (Most), Jiřina Šrůtková, MD (Hradec Králové), Marcela Charvátová, MD (Ostrava - Poruba), Bohumil Seifert, MD (Rudná), Gréta Koudelková, MD (Žatec), Miroslava Šircová, MD (Slaný), Irena Bumbová, MD (Kamenné Žehrovice), Otto Herber, MD (Veltrusy), Eva Charvátová, MD (Praha 5), Šárka Čermáková, MD (Slaný), Olga Kličková, MD (Praha 10) and Jarmila Seifertová, MD (Kladno)

*Rejchrt S, Kopáčová M, Koupil I, Voříšek V, Beránek M, Seifert B, Pozler O, Živný P, Douda T, Kolesárová M, Pintér M, Palička V, Bureš J, and the European Society for Primary Care Gastroenterology. Delta values of the ^{13}C -urea breath test in *Helicobacter pylori* positive persons with and without dyspepsia. Folia Gastroenterol Hepatol 2004; 2 (3): 105 - 110.*

Abstract. *The possible role of *Helicobacter pylori* (Hp) in functional dyspepsia is still controversial. Some authors hypothesize that excessive gastric urea production by Hp could be responsible for dyspeptic complaints. The aim of this study was to investigate the difference (delta) of the $^{13}\text{CO}_2 / ^{12}\text{CO}_2$ ratio in ^{13}C -urea breath test (^{13}C -urea-UBT) among Hp-positive persons with and without dyspepsia. Hp status was investigated by means of ^{13}C -urea-UBT in 2,478 persons, 1,230 men and 1,248 women (4 - 100 year-old, mean 40, median 38 years), randomly taken from a general non-selected population. Breath samples were analyzed by means of isotope ratio mass spectrometry (AP 2003, Analytical Precision, UK). Cut-off was 3.5 (grey zone range 3.3 - 3.7). Health status was evaluated based on data given by particular persons into their structured questionnaires. A total of 1,015 (41.0 %) persons were Hp positive and 1,399 (56.4 %) Hp negative. Sixty-four subjects (2.6 %) had a grey zone result. There was no significant difference of dyspepsia rate between Hp positive and Hp negative persons. Among Hp-positive subjects, there were 529/1,015 persons (52.1 %) symptom free, 61/1,015 patients (6.0 %) had dyspepsia as the only long-lasting symptom and 63/1,015 subjects (6.2 %) had dyspepsia associated with other co-morbidity. There was no significant difference of delta values between symptom-free Hp-positive persons and Hp-positive patients with sole long-lasting dyspepsia. Thus our results do not support the hypothesis that gastric urea overproduction could be a causative factor originating dyspeptic symptoms.*

Key words: *Helicobacter pylori, ^{13}C -urea breath test, delta over baseline, functional dyspepsia*

Rejchrt S, Kopáčová M, Koupil I, Voříšek V, Beránek M, Seifert B, Pozler O, Živný P, Douda T, Kolesárová M, Pintér M, Palička V, Bureš J, a Evropská společnost primární péče v gastroenterologii. Hodnoty delta dechového testu s ^{13}C -ureou u *Helicobacter pylori* pozitivních osob s dyspepsií a bez dyspepsie. *Folia Gastroenterol Hepatol* 2004; 2 (3): 105 - 110.

Souhrn. Možná role infekce *Helicobacter pylori* (Hp) u funkční dyspepsie je stále kontroverzní. Někteří autoři vyslovili domněnku, že výrazná produkce močoviny v žaludku účinkem Hp by mohla způsobovat dyspeptické obtíže. Cílem této studie bylo vyšetřit hodnoty delta, jako rozdílu poměrů $^{13}\text{CO}_2 / ^{12}\text{CO}_2$ dechového testu s ^{13}C -ureou u Hp pozitivních osob s dyspepsií a bez dyspepsie. Přítomnost infekce Hp byla vyšetřena pomocí dechového testu s ^{13}C -ureou u 2478 osob, 1230 mužů a 1248 žen (ve věku 4 - 100 let, průměr 40, medián 38 let), vybraných z neselektované všeobecné populace. Vzorky dechu byly analyzovány poměrovou hmotnostní spektrometrií (AP 2003, Analytical Precision, Velká Británie). Rozhraní pozitivního a negativního výsledku (cut-off) bylo 3,5, šedá zóna byla 3,3 - 3,7. Hodnocení zdravotního stavu bylo provedeno na základě údajů jednotlivých vyšetřených osob, které uvedli do strukturovaného dotazníku. Celkem 1015 osob (41,0 %) bylo Hp pozitivních a 1399 (56,4 %) bylo Hp negativních. Šedesát čtyři vyšetření (2,6 %) měl hraniční výsledek v šedé zóně. Nebyl zjištěn signifikantní rozdíl v prevalenci dyspepsie u Hp pozitivních a Hp negativních osob. Mezi Hp pozitivními bylo 529/1015 vyšetřených (52,1 %) bez subjektivních zdravotních potíží, 61/1015 (6,0 %) osob mělo dyspepsii jako jediný dlouhodobě trvající příznak a 63/1015 (6,2 %) vyšetřených mělo dyspepsii spolu s jiným onemocněním. Nebyl zjištěn signifikantní rozdíl delta hodnot dechového testu mezi Hp pozitivních osob bez dyspepsie a Hp pozitivních osob s dyspepsií jako jediným dlouhodobě trvajícím příznakem. Naše výsledky nepodporují teorie, že by močovina vytvořená v žaludku účinkem Hp byla příčinným faktorem při vzniku dyspeptických obtíží.

Klíčová slova: *Helicobacter pylori*, dechový test s ^{13}C -ureou, hodnota delta, funkční dyspepsie

The ^{13}C -urea breath test (^{13}C -urea-UBT) is the most accurate non-invasive method to diagnose *Helicobacter pylori* (Hp) infection (23). The test is based on the gastric urease activity of Hp, which splits non-radioactive stable ^{13}C -labelled urea ingested by investigated persons into NH_4^+ and ^{13}C -labelled HCO_3^- , which is expired as $^{13}\text{CO}_2$ in the exhaled breath. Expired ^{13}C -labelled carbon dioxide is measured as a $^{13}\text{CO}_2 / ^{12}\text{CO}_2$ ratio and results are expressed as the excess delta (difference between δt_1 and δt_0). The ^{13}C -urea-UBT correlates with gastric density of Hp infection (4,6,9,18,31,34,37).

The possible role of Hp infection in functional dyspepsia is still controversial (7,8,10,28,29,38,39,43). Some authors hypothesize that excessive gastric urea production by Hp could be responsible for dyspeptic complaints (5,13). The aim of this study was to assess delta values of ^{13}C -urea-UBT in Hp-positive persons with and without dyspepsia.

Materials and methods

Subjects

Nineteen general practitioner centres (7 for children & adolescents and 12 for adults) took part in the Project. A total number of 30,012 persons created this general non-selected population. In two-step

random selection, carried out centrally, 2,956 individuals older than 4 years were chosen for the study. All persons selected were invited (in writing) to participate in the study. Four hundred and forty-seven (15.1 %) of the subjects were excluded: 172 did not respond the invitation, 72 moved, 58 died (within a 6-month period between the selection and study), 55 refused to participate, 49 were employed far from their place of residency, 19 were abroad for a long-term stay, 1 was staying at an asylum elsewhere, 19 persons did not complete the breath test and 2 subjects did not fill out the questionnaire. Another 31 persons (1 %) were excluded as complete data (either from the breath samples analysis or questionnaires) was not available. All participants got detailed written information about the Project in advance and signed written consent (parents on behalf of their children).

Overall, 2,478 persons, 1,230 men and 1,248 women (4 - 100 year-old, mean 40, median 38 years) were evaluated. Health status was assessed based on data given by particular subjects on their structured questionnaires. For all data obtained, all personal identification information was deleted in compliance with the laws for the protection of confidentiality in the Czech Republic.

Urea breath test

Urea breath tests were performed in the morning after overnight fasting. Citric acid solution (3 g dissolved in 150 mL of still water) as a test drink was given initially. Five minutes later two baseline exhaled breath samples were collected into 20-mL vacutainers using a straw. Thereafter all persons ingested 100 mg ¹³C-urea for adults (Helicobacter Test Hp Plus, Utandningstester i Sverige AB, Göteborg, Sweden) or 75 mg ¹³C-urea for children and adolescents (Helicobacter Test INFAL, INFAL GmbH, Köln, Germany) dissolved in 50 mL of still water with 1 g citric acid (at time 0). Breath samples were collected in duplicate using a straw into 20-mL vacutainers after 30 minutes. Tubes with breath samples were sent to a single analytical centre by post and measured within a one-week period. Breath samples were analyzed by means of isotope ratio mass spectrometry (AP 2003, Analytical Precision, United Kingdom). Cut-off was 3.5 (grey zone range 3.3 - 3.7).

Statistics

Data were statistically treated by a Mann-Whitney test, analysis of variance and a Chi-square test using statistical software (SigmaStat, Jandel Corporation, Germany).

Results

A total of 1,015 (41.0 %) persons were Hp-positive and 1,399 (56.4 %) were Hp-negative. Sixty-four subjects (2.6 %) had a grey zone result. Among children & adolescents (4 - 18 year-old) 190/664 subjects (28.6 %) were Hp positive, among adults (over 18 years) 825/1,814 persons (46.5 %) were Hp positive ($\chi^2 = 20.754$, $p < 0.001$). There was no significant difference in the prevalence of Hp between males (516/1,230, 42.0 %) and females (499/1,248, 40.0 %), $\chi^2 = 0.369$, $p = 0.544$. There was no significant difference of dyspepsia rate between Hp-positive and Hp-negative persons. Among Hp-positive subjects, there

were 529/1,015 persons (52.1 %) symptom free who themselves felt healthy, 61/1,015 patients (6.0 %) had dyspepsia as the only long-lasting symptom (over one year) and 63/1,015 subjects (6.2 %) had dyspepsia associated with other co-morbidity and/or treatment. Remaining 362/1,015 (35.7 %) persons have had various, mostly minor health problems without dyspepsia (like allergy, arthralgias, recurrent respiratory infections, headache, low back pain, chronic bronchitis, hypertension, diabetes mellitus or ischaemic heart disease etc.).

Delta values were significantly higher in persons tested with higher (100 mg) compared to lower dose (75 mg) of ¹³C-urea both for Hp-positive and Hp-negative subjects (Table 1). There was no significant relationship between delta values and age either among Hp-positive children ($r = -0.202$, NS) or Hp-positive adults ($r = -0.107$, NS). Delta values were significantly higher in Hp-positive males when compared with Hp-positive females (Table 2). This difference was still significant when delta values were related to the body-mass index of particular subjects, median 0.520 (interquartile range 0.303 - 0.718) vs. 0.438 (0.236 - 0.675), $p = 0.009$. Baseline values of the ¹³CO₂ / ¹²CO₂ ratio were significantly lower in adult males (-23.805 ± 1.231) compared with adult females (-23.992 ± 1.000), $p = 0.044$, and between adult persons in total (-23.893 ± 1.131) and children & adolescents (-24.272 ± 1.085), $p < 0.001$. There was no significant difference of delta values between symptom-free Hp-positive persons and Hp-positive patients with sole long-lasting dyspepsia (Table 3).

Discussion

The ¹³C-urea-UBT correlates with gastric density of Hp infection (4,6,9,18,31,34,37) although not proved by all authors (22). The aim of our study was to evaluate delta values of ¹³C-urea-UBT in Hp-positive subjects with and without dyspepsia. We found no significant difference of delta values between symptom-

Table 1

Delta values in *Helicobacter pylori* positive and negative children & adolescent persons (¹³C-urea 75 mg) and adults (¹³C-urea 100 mg administered), expressed as median and interquartile range. Sixty-four persons with grey zone results are not included.

Delta	¹³ C-urea 75 mg (n = 633)	¹³ C-urea 100 mg (n = 1,781)	Significance
Hp-negative (n = 1,399)	0.525 (0.24 - 0.12)	1.560 (0.81 - 2.29)	$p < 0.001$
Hp-positive (n = 1,015)	6.110 (4.55 - 12.74)	13.285 (7.84 - 18.79)	$p < 0.001$

Table 2

Delta values in *Helicobacter pylori* positive males and females, expressed as mean \pm SD and median & interquartile range.

	Males n = 516		Females n = 499		Significance
	mean \pm SD	median interquartile range	mean \pm SD	median interquartile range	
Adults n = 825	13.785 \pm 6.024	13.970 8.615 - 19.272	12.906 \pm 7.192	11.800 7.160 - 18.182	p = 0.015
Children & adolescents n = 190	9.962 \pm 6.192	8.200 5.003 - 13.920	8.335 \pm 5.779	5.320 4.333 - 10.425	p = 0.011
Total n = 1,015	13.200 \pm 6.199	13.215 7.580 - 18.825	11.888 \pm 7.155	10.650 5.560 - 17.300	p < 0.001

Table 3

Delta values in 1,015 *Helicobacter pylori* positive persons with and without dyspepsia, expressed as mean \pm SD and median & interquartile range (IQR).

Delta values	Mean \pm SD	Median (IQR)
(A) Symptom-free subjects (n = 529)	12.022 \pm 6.413	10.935 (5.880 - 17.450)
(B) Various diseases without dyspepsia (n = 362)	12.764 \pm 6.244	11.820 (6.845 - 18.521)
A + B (n = 891)	12.312 \pm 6.354	11.330 (6.265 - 17.782)
(C) Sole long-lasting dyspepsia (n = 61)	13.182 \pm 11.195	11.540 (6.412 - 17.347)
(D) Other dyspepsia + co-morbidity (n = 63)	13.454 \pm 5.945	13.320 (8.170 - 18.380)
C + D (n = 124)	13.331 \pm 8.682	12.720 (7.893 - 18.118)

Significance:

A vs B: NS (p = 0.061); A vs C: NS (p = 0.824); A vs D: p = 0.050; B vs C: NS (p = 0.455);

B vs D: NS (p = 0.359); C vs D: NS (p = 0.222); A+B vs C+D: NS (p = 0.296).

NS - not significant.

free Hp-positive persons and Hp-positive patients with sole long-lasting dyspepsia. Based on structured health questionnaire, 61 patients have been suffering from sole long-lasting dyspeptic symptoms (one year or longer), with no evidence of organic disease and no alarm symptoms. We suppose that these patients have had functional dyspepsia, although in a substantial part of cases it was in fact an uninvestigated dyspepsia (not investigated at upper GI endoscopy), thus not-fulfilling the Rome II criteria (33). Dyspepsia in the other 63 persons was associated with other complaints, co-morbidity and/or medical treatment and was considered to be organic or secondary dyspepsia. There was a difference of delta values between this group of Hp-positive patients and Hp-positive symptom-free subjects. This finding must be interpreted with caution as these 63 persons form a very heterogeneous group of different conditions (known organic gastrointestinal disease, NSAIDs or other medical treatment for different co-morbidity etc).

There was also a significant difference of delta values between Hp-positive males and females, both for children & adolescents and adults (Table 2). This difference still remains significant even when delta values are related to body-mass index and a slight difference of baseline values is considered. Klein et al. (17) found higher urea hydrolysis rate in males and concluded that results of $^{13}\text{CO}_2 / ^{12}\text{CO}_2$ ratio are critically dependent on the amount of dilution by endogenous CO_2 production (higher in males than females) (17). According to another study (1), breath test results are not influenced by CO_2 production in otherwise healthy persons (unlike children with cystic fibrosis) and/or in case of a normal metabolic rate. Furthermore if we use mass spectrometry for the analysis, delta values are not influenced by $^{12}\text{CO}_2$ concentration as single particles are measured (as opposed to infrared spectrometry). Based on our previous study (20) we hypothesize that different time peaks in men and women are the most plausible explanation for

the difference of delta values between males and females.

Koskenpato et al. (21) found that high delta-over-baseline values were associated with antrum-predominant Hp-positive chronic gastritis and functional dyspepsia (in a subgroup of 36 patients out of 136 subjects). These patients gained symptom improvement one year after successful anti-Hp eradication therapy. Similarly as in our case, Braden et al (3) found no association between dyspeptic symptoms and density of gastric Hp colonization in their study of 1,500 persons. Chang et al. (5) studied 100 dyspeptic patients by means of ¹³C-urea-UBT and concluded that patients with functional dyspepsia and high delta values (> 58.2) could benefit from Hp eradication therapy. Franceschi et al. (13) found an increase of frequency and intensity of dyspeptic symptoms according to delta-over-baseline values (in 1,688 Hp-positive patients out of 2,520 dyspeptic subjects).

The possible role of Hp infection in the pathogenesis of functional dyspepsia is still very controversial. Several clinical studies have been published both with positive (21,24,25,30) and prevailing negative results (2,11,12,14-16,19,26,32,40,41). There are

several concepts for the possible causative role of Hp in functional dyspepsia hypothesizing that dyspeptic symptoms are caused by mediators of chronic inflammation (25), virulent strains of Hp (42), neuroplastic changes in the afferent neural pathway (leading to visceral hyperalgesia) (36), gastric dysmotility caused by Hp (27,35) or excessive gastric urea production by Hp (5,13).

To summarize our study, there was no significant difference of delta values between symptom-free Hp-positive persons and Hp-positive patients with sole long-lasting dyspepsia. Thus our results do not support the hypothesis that gastric urea overproduction would be a causative factor originating symptoms in dyspepsia.

Acknowledgements

The authors would like to express their sincerest thanks to Professor Jan Holčík, MD, DSc, Head of the Department of Social Medicine and Health Care Administration, Faculty of Medicine, Masaryk University, Brno, Czech Republic, for his kind help in preparation of the study and much appreciated suggestions for the arrangement of this Project.

REFERENCES

1. Amarri S, Coward WA, Harding M, Weaver LT. Importance of measuring CO₂-production rate when using breath tests to measure fat digestion. *Br J Nutr* 1998; 79: 541 - 545.
2. Blum AL, Talley NJ, O'Morain C, Veldhuyzen van Zanten S, Labenz J, Stolte M, Louw JA, Stubberod A, Theodors A, Sundin M, Bolling-Sternevald E, Junghard O for the Omeprazole plus Clarithromycin and Amoxicillin Effect One Year after Treatment (OCAY) Study Group. Lack of effect of treating Helicobacter pylori infection in patients with nonulcer dyspepsia. *N Engl J Med* 1998; 339: 1875 - 1881.
3. Braden B, Caspary WF, Lembcke B. Density of gastric Helicobacter pylori colonization is not associated with occurrence of dyspeptic symptoms. *Dig Dis Sci* 1997; 42: 2120 - 2123.
4. Chang MC, Chang YT, Sun CT, Wu MS, Wang HP, Lin JT. Quantitative correlation of Helicobacter pylori stool antigen (HpSA) test with ¹³C-urea breath test (13C-UBT) by the updated Sydney grading system of gastritis. *Hepatogastroenterology* 2002; 49: 576 - 579.
5. Chang YW, Min SK, Kim KJ, Han YS, Lee JH, Dong SH, Kim HJ, Kim BH, Lee JI, Chang R. Delta ¹³C-urea breath test value is a useful indicator for Helicobacter pylori eradication in patients with functional dyspepsia. *J Gastroenterol Hepatol* 2003; 18: 726 - 731.
6. Chen X, Haruma K, Kamada T, Mihara M, Komoto K, Yoshihara M, Sumii K, Kajiyama G. Factors that affect results of the 13C urea breath test in Japanese patients. *Helicobacter* 2000; 5: 98 - 103.
7. Chey WD, Moayyedi P. Review article: uninvestigated dyspepsia and non-ulcer dyspepsia - the use of endoscopy and the roles of Helicobacter pylori and antisecretory therapy. *Aliment Pharmacol Ther* 2004; 19, Suppl 1: 1 - 8.
8. Delaney BC, Moayyedi P, Forman D. Initial management strategies for dyspepsia (Cochrane Review). In: *The Cochrane Library*, Issue 1, 2004. Chichester: John Wiley & Sons, 2004.
9. Ellenrieder V, Glasbrenner B, Stoffels C, Weiler S, Bode G, Moller P, Adler G. Qualitative and semi-quantitative value of a modified ¹³C-urea breath test for identification of Helicobacter pylori infection. *Eur J Gastroenterol Hepatol* 1997; 9: 1085 - 1089.
10. Fixa B. The role of Helicobacter pylori in chronic gastritis and functional dyspepsia. *Čes Slov Gastroenterol Hepatol* 2004; 58, Suppl: 44 - 46.
11. Fixa B, Komárková O, Nožička Z. Does exist a difference between the prevalence of the main dyspeptic complaints in patients with functional dyspepsia having Helicobacter pylori and those without? *Gut* 2002; 51, Suppl 3: A187.
12. Fixa B, Komárková O, Nožička Z. Long-term follow-up of patients with functional dyspepsia. Dependence of complaints on Helicobacter pylori infection? (in Czech). *Čes Slov Gastroenterol Hepatol* 2002; 56: 171 - 176.
13. Franceschi F, Armuzzi A, Cremonini F, Carloni E, Zocco MA, Di Caro S, Padalino C, Genta RM, Pola P, Gasbarrini G, Gasbarrini A. Delta ¹³CO₂ excretion and expression of dyspeptic symptoms in patients evaluated for Helicobacter pylori infection by ¹³C-urea breath test. *Dig Dis Sci* 2002; 47: 804 - 808.
14. Froelich F, Gonvers J-J, Wietlisbach V, Burnand B, Hildebrand P, Schneider C, Saraga E, Beglinger C, Vader J-P. Helicobacter pylori eradication treatment does not benefit patients with non-ulcer dyspepsia. *Am J Gastroenterol* 2001; 96: 2329 - 2336.
15. Gisbert JP, Cruzado AI, Garcia-Gravalos R, Pajares JM. Lack of benefit of treating Helicobacter pylori infection in patients with functional dyspepsia. Randomized one-year follow-up study. *Hepatogastroenterology* 2004; 51: 303 - 308.
16. Greenberg PD, Cello JP. Lack of effect of treatment for Helicobacter pylori on symptoms of non-ulcer dyspepsia. *Arch Intern Med* 1999; 159: 2283 - 2288.

17. Klein PD, Malaty HM, Czinn SJ, Emmons SC, Martin RF, Graham DY. Normalizing results of ¹³C-urea breath testing for CO₂ production in children. *J Pediatr Gastroenterol Nutr* 1999; 29: 297 - 301.
18. Kobayashi D, Eishi Y, Ohkusa T, Ishige T, Suzuki T, Minami J, Yamada T, Takizawa T, Koike M. Gastric mucosal density of *Helicobacter pylori* estimated by real-time PCR compared with results of urea breath test and histological grading. *J Med Microbiol* 2002; 51: 305 - 311.
19. Koelz HR, Arnold R, Stolte M, Fischer M, Blum AL, the FROSCHE Study Group. Treatment of *Helicobacter pylori* in functional dyspepsia resistant to conventional management: a double blind randomised trial with a six month follow up. *Gut* 2003; 52: 40 - 46.
20. Kopáčková M, Bureš J, Voříšek V, Konštický M, Rejchrt S, Živný P, Palička V. Diagnostics of *Helicobacter pylori* by means of ¹³C breath test: clinical reproducibility of the test (in Czech). *Klin Biochem Metab* 1999; 7(28): 213 - 216.
21. Koskenpato J, Färkkilä M, Sipponen P. *Helicobacter pylori* and different topographic types of gastritis: treatment response after successful eradication therapy in functional dyspepsia. *Scand J Gastroenterol* 2002; 37: 778 - 784.
22. Lewis JD, Kroser J, Bevan J, Furth EE, Metz DC. Urease-based test for *Helicobacter pylori* gastritis. Accurate for diagnosis but poor correlation with disease severity. *J Clin Gastroenterol* 1997; 415 - 420.
23. Malfertheiner P, Mégraud F, O'Morain C, Hungin APS, Jones R, Axon A, Graham DY, Tytgat G, Asaka M, Bazzoli F, Birkner B, Bureš J, Burette A, Bytzer P, Castro L, Culhane A, de Boer W, De Korwin J, De Koster E, de Wit N, Deltenre M, Dent J, Di Mario F, Dragosics B, Färkkilä M, Forman D, Freston J, Gasbarrini G, Goh K, Graham D, Hameeteman W, Hawkey C, Hirschl A, Hunt R, Jaup B, Kimura K, Kist M, Klotz P, Koletzko S, Kuipers E, Labenz J, Ladas S, Lam SK, Lauritsen K, Lerang F, Lionis C, Loft D, Louw J, McColl K, Mendonca-Santos J, Michetti P, Misiewicz J, Mössner J, Niv Y, Nowak A, Parajés-García J, Pilotto A, Pounder R, Quina M, Rácz I, Rauws E, Rodrigo Saez L, Rokkas T, Segal I, Seifert B, Sipponen P, Sjölundh C, Solcia E, Stockbrügger R, Sung J, Surrenti C, Tulassay Z, Unge P, Vaira D, Vakil N, Veldhuyzen van Zanten S, Wadström T. Current concepts in the management of *Helicobacter* infection - The Maastricht 2-2000 Consensus Report. *Aliment Pharmacol Ther* 2002; 16: 167 - 180.
24. Malfertheiner P, Mössner J, Fischbach W, Layer P, Leodolter A, Stolte M, Demleitner K, Fuchs W. *Helicobacter pylori* is beneficial in the treatment of functional dyspepsia. *Aliment Pharmacol Ther* 2003; 18: 615 - 625.
25. McColl K, Murray L, El-Omar E, Dickson A, El-Nujumi A, Wirz A, Kelman A, Penny C, Knill-Jones R, Hilditch T. Symptomatic benefit from eradicating *Helicobacter pylori* infection in patient with nonulcer dyspepsia. *N Engl J Med* 1998; 339: 1869 - 1874.
26. McNamara D, Buckley M, Gilvarry J, O'Morain C. Does *Helicobacter pylori* eradication affect symptoms in nonulcer dyspepsia: a 5-year follow-up study. *Helicobacter* 2002; 7: 317 - 321.
27. Miyaji H, Azuma T, Ito S, Abe Y, Ono H, Suto H, Ito Y, Yamazaki Y, Kohli Y, Kuriyama M. The effect of *Helicobacter pylori* eradication therapy on gastric antral myoelectrical activity and gastric emptying in patients with non-ulcer dyspepsia. *Aliment Pharmacol Ther* 1999; 13: 1473 - 1480.
28. Moayyedi P, Deeks J, Talley NJ, Denaley B, Forman D. An update of the Cochrane systematic review of *Helicobacter pylori* eradication therapy in nonulcer dyspepsia: resolving discrepancy between systematic reviews. *Am J Gastroenterol* 2003; 98: 2621 - 2626.
29. Moayyedi P, Soo S, Deeks J, Delaney B, Harris A, Innes M, Oakes R, Wilson S, Roafe A, Bennett C, Forman D. Eradication of *Helicobacter pylori* for non-ulcer dyspepsia (Cochrane Review). In: *The Cochrane Library*, Issue 1, 2004. Chichester: John Wiley & Sons, 2004.
30. O'Morain C, Gilvarry J. Eradication of *Helicobacter pylori* in patients with non-ulcer dyspepsia. *Scand J Gastroenterol* 1993; 38, Suppl 196: 30 - 33.
31. Perri F, Clemente R, Pastore M, Quitadamo M, Festa V, Bisceglia M, Li Bergoli M, Lauriola G, Leandro G, Ghos Y, Rutgeerts P, Andriulli A. The ¹³C-urea breath test as a predictor of intragastric bacterial load and severity of *Helicobacter pylori* gastritis. *Scand J Clin Lab Invest* 1998; 58: 19 - 28.
32. Perri F, Festa V, Grossi E, Garbagna N, Leandro G, Andriulli A, NUD-LOOK Study Group. Dyspepsia and *Helicobacter pylori* infection: a prospective multicentre observational study. *Dig Liver Dis* 2003; 35: 157 - 164.
33. Rome II. *The Functional Gastrointestinal Disorders*. DA Drossman, E Corazziari, NJ Talley, WG Thompson, WE Whitehead, eds. 2nd Ed. McLean: Degnon Assoc, 2000: 764.
34. Sheu BS, Lee SC, Yang HB, Lin XZ. Quantitative result of ¹³C urea breath test at 15 minutes may correlate with the bacterial density of *H. pylori* in the stomach. *Hepatogastroenterology* 1999; 46: 2057 - 2062.
35. Simren M, Vos R, Janssens J, Tack J. Unsuppressed postprandial phasic contractility in the proximal stomach in functional dyspepsia: relevance to symptoms. *Am J Gastroenterol* 2003; 98: 2169 - 2175.
36. Stanghellini V, Barbara G, de Giorgio R, Tosetti C, Cogliandro R, Cogliandro L, Salvioli B, Corinaldesi R. Review article: *Helicobacter pylori*, mucosal inflammation and symptom perception - new insights into an old hypothesis. *Aliment Pharmacol Ther* 2001; 15, Suppl 1: 28 - 32.
37. Suto H, Azuma T, Ito Y, Miyaji H, Yamazaki Y, Kohli Y, Kuriyama M. Endoscopic ¹³C-urea breath test for quantification of *Helicobacter pylori* infection. *J Gastroenterol Hepatol* 2000; 15: 161 - 167.
38. Talley NJ. A critique of therapeutic trials in *Helicobacter pylori*-positive functional dyspepsia. *Gastroenterology* 1994; 106: 1174 - 1183.
39. Talley NJ. Dyspepsia management in the millennium: the death of test and treat? *Gastroenterology* 2002; 122: 1521 - 1525.
40. Talley NJ, Janssens J, Lauritsen K, Rácz I, Bolling-Sternevald E on behalf of the Optimal Regimen Cures *Helicobacter* Induced Dyspepsia (ORCHID) Study Group. Eradication of *Helicobacter pylori* in functional dyspepsia: randomised double blind placebo controlled trial with 12 months' follow up. *Br Med J* 1999; 318: 833 - 837.
41. Talley NJ, Vakil N, Ballard ED, Fennerty MB. Absence of benefit of eradicating *Helicobacter pylori* in patients with nonulcer dyspepsia. *N Engl J Med* 1999; 341: 1106 - 1111.
42. Treiber G, Schwabe M, Ammon S, Walker S, Klotz U, Malfertheiner P. Dyspeptic symptoms associated with *Helicobacter pylori* infection are influenced by strain and host specific factors. *Aliment Pharmacol Ther* 2004; 19: 219 - 231.
43. Vakil N. Dyspepsia, non-ulcer dyspepsia, and *Helicobacter pylori*. *Rev Gastroenterol Disord* 2001; 1: 139 - 146.

Correspondence to:

Stanislav Rejchrt, MD, PhD, Clinical Centre, 2nd Department of Medicine, Charles University Teaching Hospital, Sokolská 581, 500 05 Hradec Králové, Czech Republic
E-mail: rejchrt@lfhk.cuni.cz

